低剂量糖皮质激素治疗成人心源性休克(COCCA):随机对照试验研究方案
本研究为多中心、随机、双盲、安慰剂对照试验,计划在法国招募380例成人心源性休克患者,按1:1随机分配至治疗组或对照组。治疗组给予氢化可的松(50 mg静脉推注,每6小时一次)和氟氢可的松(50 μg每日一次肠内给药),持续7天或至ICU出院。主要终点为第7天无儿茶酚胺天数,次要终点包括28天和90天发病率及全因死亡率。
要点
- 试验评估早期低剂量糖皮质激素对成人心源性休克休克逆转的影响。
- 治疗组使用氢化可的松50 mg每6小时静脉推注联合氟氢可的松50 μg每日一次肠内给药。
- 主要终点为第7天无儿茶酚胺天数,随访90天,按意向性治疗分析。
核心结论
- 该试验将为低剂量糖皮质激素治疗心源性休克的有效性提供有价值的证据;若有效,该疗法可能改善结局并成为心源性休克患者的辅助治疗。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,在法国内科、心脏科及综合ICU招募成人心源性休克患者。
- 计划招募380例患者,按1:1比例随机分配至治疗组或对照组(每组190例)。
- 治疗组给予氢化可的松(50 mg静脉推注,每6小时一次)和氟氢可的松(50 μg每日一次肠内给药),持续7天或至ICU出院。
- 每个患者随访90天,所有分析按意向性治疗进行。
关键数值与推荐
- 主要终点为第7天无儿茶酚胺天数。
- 次要终点包括随机化后28天和90天的发病率及全因死亡率。
- 预设亚组分析包括:心脏术后、心肌梗死、依托咪酯使用、血管加压药使用及根据促肾上腺皮质激素刺激试验的肾上腺特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiogenic shock (CS) is a life-threatening condition characterized by circulatory insufficiency caused by an acute dysfunction of the heart pump. The pathophysiological approach to CS has recently been enriched by the tissue consequences of low flow, including inflammation, endothelial dysfunction, and alteration of the hypothalamic-pituitary-adrenal axis. The aim of the present trial is to evaluate the impact of early low-dose corticosteroid therapy on shock reversal in adults with CS. METHOD/DESIGN: This is a multicentered randomized, double-blind, placebo-controlled trial with two parallel arms in adult patients with CS recruited from medical, cardiac, and polyvalent intensive care units (ICU) in France. Patients will be randomly allocated into the treatment or control group (1:1 ratio), and we will recruit 380 patients (190 per group). For the treatment group, hydrocortisone (50 mg intravenous bolus every 6 h) and fludrocortisone (50 μg once a day enterally) will be administered for 7 days or until discharge from the ICU. The primary endpoint is catecholamine-free days at day 7. Secondary endpoints include morbidity and all-cause mortality at 28 and 90 days post-randomization. Pre-defined subgroups analyses are planned, including: postcardiotomy, myocardial infarction, etomidate use, vasopressor use, and adrenal profiles according the short corticotropin stimulation test. Each patient will be followed for 90 days. All analyses will be conducted on an intention-to-treat basis. DISCUSSION: This trial will provide valuable evidence about the effectiveness of low dose of corticosteroid therapy for CS. If effective, this therapy might improve outcome and become a therapeutic adjunct for patients with CS. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03773822 . Registered on 12 December 2018.
引用
- Mekontso Dessap A, Bagate F, Delmas C, et al. Low-dose corticosteroid therapy for cardiogenic shock in adults (COCCA): study protocol for a randomized controlled trial. Trials. 2022. PMID: 34980224. doi:10.1186/s13063-021-05947-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。